Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P43405: Variant p.Pro342Thr

Tyrosine-protein kinase SYK
Gene: SYK
Feedback?
Variant information Variant position: help 342 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Proline (P) to Threonine (T) at position 342 (P342T, p.Pro342Thr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and hydrophobic (P) to medium size and polar (T) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In IMD82; constitutively active protein tyrosine kinase activity. Any additional useful information about the variant.


Sequence information Variant position: help 342 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 635 The length of the canonical sequence.
Location on the sequence: help PYEPELAPWAADKGPQREAL P MDTEVYESPYADPEEIRPKE The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         PY--EPELAPWAADKGPQREALPMDTEVYESPYADPEEIRPKE

Mouse                         PY--EPTGGPWGPDRGLQREALPMDTEVYESPYADPEEIRP

Rat                           PY--EPTGGAWGPDRGLQREALPMDTEVYESPYADPEEIRP

Pig                           PY--ESDRGPWANEREAQREALPMDTEVYESPYADPEEIRP

Chicken                       PYVLQRARGLIGAEKGDQREALPMDTEVYESPYADPDEIKP
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 635 Tyrosine-protein kinase SYK
Region 260 – 370 Interdomain B
Modified residue 323 – 323 Phosphotyrosine; by LYN
Modified residue 345 – 345 Phosphothreonine
Modified residue 348 – 348 Phosphotyrosine
Modified residue 350 – 350 Phosphoserine
Modified residue 352 – 352 Phosphotyrosine
Helix 342 – 344



Literature citations
Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice.
Wang L.; Aschenbrenner D.; Zeng Z.; Cao X.; Mayr D.; Mehta M.; Capitani M.; Warner N.; Pan J.; Wang L.; Li Q.; Zuo T.; Cohen-Kedar S.; Lu J.; Ardy R.C.; Mulder D.J.; Dissanayake D.; Peng K.; Huang Z.; Li X.; Wang Y.; Wang X.; Li S.; Bullers S.; Gammage A.N.; Warnatz K.; Schiefer A.I.; Krivan G.; Goda V.; Kahr W.H.A.; Lemaire M.; Lu C.Y.; Siddiqui I.; Surette M.G.; Kotlarz D.; Engelhardt K.R.; Griffin H.R.; Rottapel R.; Decaluwe H.; Laxer R.M.; Proietti M.; Hambleton S.; Elcombe S.; Guo C.H.; Grimbacher B.; Dotan I.; Ng S.C.; Freeman S.A.; Snapper S.B.; Klein C.; Boztug K.; Huang Y.; Li D.; Uhlig H.H.; Muise A.M.;
Nat. Genet. 53:500-510(2021)
Cited for: INVOLVEMENT IN IMD82; VARIANTS IMD82 THR-342; THR-353; ILE-450; PHE-550 AND TYR-550; CHARACTERIZATION OF VARIANTS IMD82 THR-342; THR-353; ILE-450; PHE-550 AND TYR-550; FUNCTION; CATALYTIC ACTIVITY;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.